XSHG688108
Market cap515mUSD
Jan 10, Last price
9.15CNY
1D
-1.61%
1Q
-9.32%
IPO
-51.51%
Name
Sino Medical Sciences Technology Inc
Chart & Performance
P/E
—
P/S
11.02
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.12%
Rev. gr., 5y
-2.04%
Revenues
343m
+77.99%
Net income
-40m
CFO
57m
Dividend
Jul 10, 20200.1 CNY/sh
Earnings
Jun 05, 2025
Profile
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional devices in China. Its products include drug-eluting stents, balloon catheters, coronary stents, and transcatheter mitral valve replacement devices. Sino Medical Sciences Technology Inc. has a clinical collaboration agreement with The National University of Ireland Galway. The company was founded in 2007 and is headquartered in Tianjin, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 343,258 77.99% | 192,854 -0.77% | ||||||
Cost of revenue | 353,728 | 307,316 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (10,471) | (114,462) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (24,457) | |||||||
Tax Rate | ||||||||
NOPAT | 13,986 | (114,462) | ||||||
Net income | (39,630) | |||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 69,271 | 46,484 | ||||||
Long-term debt | 100,141 | 23,655 | ||||||
Deferred revenue | 20,999 | 1,995 | ||||||
Other long-term liabilities | 56,461 | 11,402 | ||||||
Net debt | (33,232) | (152,237) | ||||||
| Cash flow | ||||||||
Cash from operating activities | 56,840 | |||||||
CAPEX | (67,669) | |||||||
Cash from investing activities | (193,041) | |||||||
Cash from financing activities | 122,316 | 116,858 | ||||||
FCF | 13,815 | (117,145) | ||||||
| Balance | ||||||||
Cash | 188,640 | 203,423 | ||||||
Long term investments | 14,003 | 18,952 | ||||||
Excess cash | 185,481 | 212,733 | ||||||
Stockholders' equity | 218,936 | 496,937 | ||||||
Invested Capital | 898,120 | 742,558 | ||||||
ROIC | 1.70% | |||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 396,300 | 410,000 | ||||||
Price | 12.55 119.79% | 5.71 -30.45% | ||||||
Market cap | 4,973,570 112.45% | 2,341,100 -30.45% | ||||||
EV | 4,982,031 | 2,229,262 | ||||||
EBITDA | 52,339 | (51,296) | ||||||
EV/EBITDA | 95.19 | |||||||
Interest | 3,929 | 2,549 | ||||||
Interest/NOPBT | ||||||||